<pare< th=""><th>ent Name></th></pare<>	ent Name>
<pare< th=""><th>ent Address1></th></pare<>	ent Address1>
<pare< th=""><th>ent Address2></th></pare<>	ent Address2>
<city< th=""><th>></th></city<>	>
<post< th=""><th>tcode></th></post<>	tcode>
<date< td=""><td>>></td></date<>	>>
Dear	<parent name="">,</parent>
Re:	Pre-clinic attendance information about the PREDNOS 2 study. (Short course daily prednisolone therapy at the time of upper respiratory tract infection (URTI) in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study).
Patie	nt Name:
Patie	nt DoB:
Patie	nt NHS No:

Your child is due to be seen at clinic on <insert next clinic assessment date>. In advance of this clinic assessment I am writing to give you some information about the PREDNOS 2 study which you may wish to consider. The PREDNOS 2 study will investigate whether giving a 6 day course of daily prednisolone at the time of development of URTI (common cold) will reduce the risk of relapse developing. To enter the study, children and young adults (under 19 years of age) with steroid sensitive nephrotic syndrome need to have suffered two disease relapses in the last 12 months.

I have enclosed information sheets for you/your child to look at before your child's next clinic assessment. Please take time to decide whether or not you wish your child to take part. If you have any questions or queries about the study please don't hesitate to contact me <insert responsible clinician name>. Please take time to discuss the study with your family and friends if you would like to. When you attend your next clinic appointment if you/your child would like to join the study you can sign a consent/assent form and be entered in the study. You will have plenty of time at your next clinic assessment to discuss the study further and to have any questions that you may have about the study answered. Taking part in the study is entirely voluntary, it is up to you and your child to decide whether you would like to join or not and your decision will not affect the standard of care your child receives.

If you have any queries please don't hesitate to contact me.

Yours sincerely,

<insert responsible clinician name>

PREDNOS 2 Study Office, Birmingham Clinical Trials Unit (BCTU), Institute of Applied Health Research, College of Medical and Dental Sciences, Public Health Building, University of Birmingham, Birmingham, B15 2TT.

Web address: www.birmingham.ac.uk/PREDNOS2.

EudraCT Number: 2012-003476-